The researchers found that new tests in the field of nuclear medicine can give a useful result for patients with type I diabetes. About this writes The Journal of Nuclear Medicine.
The new method of positron-emission tomography (PET) can measure the mass of beta cells, which will significantly expand the possibilities of monitoring and conducting therapy. According to the American Association for the Study of Diabetes, about 1.25 million American children and adults have type I diabetes.
Jason Bini, Dr. Yale University in New Haven, Connecticut, explains the importance of discoveries for patients in terms of tracking their beta cells:
«Beta cell mass includes both functional and non-functional beta cells. Many indirect methods for measuring the function of beta cells depend on factors such as the level of glucose and insulin, and are not able to measure non-functional (sleeping) beta cells that can react to treatment. This work is so important because the absorption of the radio radiator measured on PET CT can open treatment options. For example, if a person has a low function of beta cells with a high signal in PET scanning, it can determine it as a patient with sleeping beta cells that can react to treatment aimed at existing cells. If the patient has a low feature of beta cells and a low signal in PET (very little viable or sleeping beta cells), this person may be a beta transplant candidate. «
Beta cells and nervous fabrics have common cell receptors, so Yale researchers checked the brain radioligands on their ability to identify beta cells. Then 12 healthy people and two patients with type I diabetes were dynamic PET-CT scan, which gave accurate results for further successful treatment and confirmed the effectiveness of the theory.
In diabetes mellitus I, the type of pancreas ceases to produce insulin to split blood sugar. Currently, this disease is incurable. The only way to maintain the life of the patient is the daily injections of insulin throughout life.
Earlier we wrote that